BIOVERSYS (COVID-19) (IDFF)
The status, timeline and source of this project. A free account opens every field.
Source: European Investment Bank (EIB)
The project supports the company's research and development (R&D) investments in the field of antimicrobial resistance, in particular tuberculosis and nosocomial infections. By targeting hospital-acquired infections the project also addresses COVID-19, as such co-infections very often occur in hospitalised COVID-19 patients, leading to serious complications.
- Status
- Under Construction
- Sector
- Hospital, Government
- Location
- Switzerland
- Updated
- 22 Jul 2026
- Source
- European Investment Bank (EIB)
ConstructChat
Ask ConstructChat about BIOVERSYS (COVID-19) (IDFF)
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
Sponsoring Agency |
Status
Original status | signed |
Taiyo status | Under Construction |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The project supports the company's research and development (R&D) investments in the field of antimicrobial resistance, in particular tuberculosis and nosocomial infections. By targeting hospital-acquired infections the project also addresses COVID-19, as such co-infections very often occur in hospitalised COVID-19 patients, leading to serious complications. |
Original sector | Industry |
Location
Country | Switzerland |
Source
Source | European Investment Bank (EIB) |
URL |
More Details
Record type | Project |
Sector | Hospital, Government |
Article published date | 2025-07-28 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Switzerland
- AGORA Cancer Centre, Lausanne
- SUN2CHEM
- Helsinn New Cytotoxic Plant, Biasca
- Merck Biotech Development Facility, Corsier-sur-Vevey, Switzerland
- Thermo Fisher Scientific’s Biologics Manufacturing Facility, Lengnau, Switzerland
- Caring for and improving the quality of life of terminal patients and their families
- Development of an accurate and reliable innovative solution for tumour destruction in interventional radiology
- Collaboration between Research Institutions, Small and Medium Enterprises and Hospital Centers for the development of new anti Leukemia therapies based on antibodies and nanoparticles
